Buffey · Sports medicine (Auckland, N.Z.) 2022 · systematic review and meta-analysis · n=7 studies

The Acute Effects of Interrupting Prolonged Sitting Time in Adults with Standing and Light-Intensity Walking on Biomarkers of Cardiometabolic Health in Adults: A Systematic Review and Meta-analysis.

Level 1 - systematic review of randomized trials

Systematic review and meta-analysis of randomized crossover trials

PubMed 35147898 · doi:10.1007/s40279-022-01649-4 · record verified 2026-08-26

What was done

Authors conducted a systematic review and meta-analysis of randomized crossover trials with at least three intervention arms in adults aged 18 years and older (predominantly overweight or with obesity). The review evaluated the acute (single-day) effects of interrupting prolonged sitting with frequent short bouts of standing versus light-intensity walking compared against continuous prolonged sitting. Primary pooled outcomes were postprandial glucose (7 studies), postprandial insulin (4 studies), and systolic blood pressure (3 studies), quantified via standardized mean differences (Cohen's d).

What was found

Compared to continuous sitting: - Standing breaks reduced postprandial glucose (Δ = -0.31, 95% CI -0.60 to -0.03, p < 0.04), but had no significant effect on postprandial insulin or systolic blood pressure. - Light-intensity walking breaks significantly reduced postprandial glucose (Δ = -0.72, 95% CI -1.03 to -0.41, p < 0.001) and postprandial insulin (Δ = -0.83, 95% CI -1.18 to -0.48, p < 0.001), with no significant effect on systolic blood pressure. - Comparing walking breaks directly to standing breaks showed walking produced significantly greater reductions in both glucose (Δ = -0.30, 95% CI -0.52 to -0.08, p < 0.009) and insulin (Δ = -0.54, 95% CI -0.75 to -0.33, p < 0.001).

Why it matters

This meta-analysis quantifies the dose-dependent metabolic benefits of breaking sedentary time, demonstrating that while standing offers modest glucose-lowering benefits, light ambulation is substantially more effective for mitigating acute postprandial glycemic and insulinemic excursions.

Limits

The total number of included studies was small (7 trials; only 4 for insulin and 3 for blood pressure), and the abstract does not report the total participant count. All included studies examined only acute, single-day laboratory interventions, precluding conclusions about long-term cardiometabolic adaptations, clinical disease endpoints, or feasibility in free-living environments.

Cited by